Intellia Therapeutics Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, Intellia Therapeutics stock has a consensus rating of "Buy" and an average price target of $26.63. The average 1-year stock price forecast is 99.63% higher than the current stock price, while the lowest is $8.00 (-40.03%) and the highest is $95 (+612.14%).

Price Target: $26.63 (+99.63%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$8.00	$26.63	$19	$95
Change	-40.03%	+99.63%	+42.43%	+612.14%

Analyst Ratings

The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	10	11	13	13	11	11
Buy	2	1	1	1	1	1
Hold	11	11	9	9	9	8
Sell	1	1	1	1	1	1
Strong Sell	1	1	1	1	1	1
Total	25	25	25	25	23	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Myles Minter William Blair	William Blair	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Jun 15, 2026
Debanjana Chatterjee JonesTrading	JonesTrading	Buy Reiterates $29	Buy	Reiterates	$29	+117.39%	May 28, 2026
Brian Cheng J.P. Morgan	J.P. Morgan	Sell Maintains $8	Sell	Maintains	$8	-40.03%	May 14, 2026
Terence Flynn Morgan Stanley	Morgan Stanley	Hold Maintains $15	Hold	Maintains	$15	+12.44%	May 13, 2026
William Pickering Bernstein	Bernstein	Hold Reiterates $13 → $17	Hold	Reiterates	$13 → $17	+27.44%	May 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

59.97M

from 67.67M

-11.38%

from 67.67M

Revenue Next Year

265.93M

from 59.97M

343.43%

from 59.97M

EPS This Year

-3.17

from -3.81

EPS Next Year

-1.80

from -3.17

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	33.05M	52.12M	36.28M	57.88M	67.67M	59.97M
Revenue Growth	-43.01%	57.69%	-30.40%	59.55%	16.92%	-11.38%
Gross Profit	-196.75M	-367.86M	-398.79M	-349.04M	-256.78M	59.97M
Gross Margin	-595.27%	-705.78%	-1,099.36%	-603.07%	-379.46%	100.00%
Operating Income	-267.85M	-458.16M	-515.29M	-534.26M	-440.99M	-429.50M
Net Income	-267.89M	-474.19M	-481.19M	-519.02M	-412.69M	-414.35M
EPS	-	-	-	-	-3.81	-3.17
Free Cash Flow	-69.57M	-256.18M	-268.21M	-133.38M	-233.29M	-334.28M
No. Analysts	-	-	-	-	-	20

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	100.0M
Avg	60.0M
Low	15.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	47.8%
Avg	-11.4%
Low	-77.8%

EPS Forecast

EPS	2026	2027	2028
High	-2.76
Avg	-3.17
Low	-3.75

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-